Eisai Co., Ltd. and MGI PHARMA, Inc. have announced that Eisai will acquire MGI PHARMA for approximately $3.9 billion. Eisai is a research-based company focusing on discovery, development, and marketing of therapeutic products in the fields of neuroscience, gastrointestinal disorders, and oncology. MGI PHARMA is a biopharmaceutical company that focuses on oncology. MGI PHARMA currently has a number of products on the market in the U.S., including Aloxi® (palonosetron hydrochloride) for injection,
Dacogen® (decitabine) for injection, and Gliadel® Wafer (polifeprosan 20 with carmustine implant), and also has a large pipeline of therapeutic agents in various clinical trials. Eisai's acquisition of MGI PHARMA is in line with its strategic plan of strengthening its worldwide position in the field of oncology.
Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular biologist and founding author of Patent Docs.
Comments